Browse our 1,000+ Publications​

Latest Publications

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Falchi L, et al.
Blood
November 2025
Authors and Affiliates
Lorenzo Falchi,1 Anna Sureda,2 Sirpa Leppä,3 Joost S. P. Vermaat,4 Marcel Nijland,5 Jacob Haaber Christensen,6 Sven de Vos,7 Harald Holte,8 Reid W. Merryman,9 Pieternella J. Lugtenburg,10, * Pau Abrisqueta,11 Kim M. Linton,12 Gauri Sunkersett,13 Daniela Hoehn,14 Ali Rana,14 Aqeel Abbas,14 Jennifer Marek,14 Yi Hao,14 Andrew J. Steele,14 Christopher Morehouse,14 Martin Hutchings,15 and David Belada16 1 Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; 2 Clinical Hematology Department, Institut Catala` d’Oncologia, L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain; 3 Department of Oncology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; 4 Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands; 5 Department of Hematology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands; 6 Department of Haematology, Odense University Hospital, Odense, Denmark; 7 Department of Medicine, Hematology/Oncology, Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA; 8 Department of Oncology, Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway; 9 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 10Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands; 11Department of Hematology, Hospital Universitario Vall d’Hebron, Barcelona, Spain; 12Division of Cancer Sciences, The Christie NHS Foundation Trust, Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom; 13AbbVie, North Chicago, IL; 14Genmab, Plainsboro, NJ; 15Department of Haematology, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark; and 164th Department of Internal Medicine, Haematology, Hospital and Faculty of Medicine, Charles University, Hradec Kralové, ´ Czech Republic

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in theLINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

Lee H, et al.
Clinical Lymphoma Myeloma & Leukemia
November 2025
Authors and Affiliates
Hans C. Lee,1 Jeffrey A. Zonder,2 Madhav V. Dhodapkar,3 Sundar Jagannath,4 James E. Hoffman,5 Attaya Suvannasankha,6 Mansi R. Shah,7 Suzanne Lentzsch,8 Rachid Baz,9 Joseph J. Maly,10 Swathi Namburi,11 Matthew J. Pianko,12 Jing Christine Ye,1 Ka Lung Wu,13 Rebecca Silbermann,14 Chang-Ki Min,15 Marie-Christiane Vekemans,16 Markus Munder,17 Ja Min Byun,18 Joaquín Martínez-Lopez,19 Michelle DeVeaux,20 Tito Roccia,20 Dhruti Chokshi,20 Megan Seraphin,20 Kate Knorr,20 Anita Boyapati,20 Anasuya Hazra,20 Karen Rodriguez Lorenc,20 Glenn S. Kroog,20 Naresh Bumma,21 Joshua Richter4 1The University of Texas MD Anderson Cancer Center, Houston, TX 2Karmanos Cancer Institute, Detroit, MI 3Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 4Icahn School of Medicine at Mount Sinai, New York, NY 5Department of Medicine, University of Miami Health System, Miami, FL 6Department of Medicine, Indiana University Simon Cancer Center and Richard L. Roudebush VAMC, Indianapolis, IN 7Department of Medicine, Rutgers Cancer Institute, New Brunswick, NJ 8Columbia University Irving Medical Center, New York, NY 9Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 10Norton Cancer Institute, Louisville, KY 11Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA 12Department of Internal Medicine, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 13Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium 14Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 15Department of Hematology, College of Medicine, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea 16Hematology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium 17Department of Internal Medicine III, Universitätsmedizin Mainz, Mainz, Germany 18Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea 19Hospital Universitario 12 de Octubre, i+12, School of Medicine Universidad Complutense, CNIO, Madrid, Spain 20Regeneron Pharmaceuticals, Inc., Tarrytown, NY 21Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL

Short N, et al.
Blood Cancer Journal
October 2025
Authors and Affiliates
Nicholas J. Short 1,5✉, Elias Jabbour 1,5, Walid Macaron1,2,5, Nitin Jain1 , Fadi G. Haddad 1 , Sanam Loghavi 3 , Tapan M. Kadia 1 , Partow Kebriaei4 , Eitan Kugler1 , Jairo Matthews1 , Rebecca Garris1 , Farhad Ravandi 1 and Hagop Kantarjian 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 3 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4 Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5 These authors contributed equally: Nicholas J. Short, Elias Jabbour, Walid Macaron.

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study

Bahlis N, et al.
Leukemia & Lymphoma
October 2025
Authors and Affiliates
Nizar J. Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Tomasz Wrobel, Vania Hungria, Britta Besemer, Edvan Crusoe, Trine Silkjaer, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A. Dimopoulos, Mark-David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wroblewski, Alba Tuozzo, Robin Carson & Thierry Facon a Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; bBarbara Ann Karmanos Cancer Institute, Detroit, MI, USA; c Department of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France; dVejle Hospital, University of Southern Denmark, Vejle, Denmark; e Division of Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy; f Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland; gClínica Medica São Germano, São Paulo, Brazil; hAbteilung für Innere Medizin II, Universitätsklinikum Tübingen der Eberhard-Karls-Universität, Tübingen, Germany; i Hospital São Rafael, Instituto D’Or de Pesquisa e Ensino and Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia-HUPES-UFBA, Salvador, Brazil; j Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; k Université de Toulouse, CHU de Toulouse, Service d’Hématologie, Toulouse, France; l Hematology Department, University Hospital Hôtel-Dieu, Nantes, France; mZNA Stuivenberg, Antwerp, Belgium; nEvangelismos Hospital, Athens, Greece; o Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece; pDepartment of Medicine, Korea University, Seoul, South Korea; qAlbert Schweitzer Hospital, Dordrecht, The Netherlands; r Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy; s Johnson & Johnson, Washington, PA, USA; t Johnson & Johnson, Raritan, NJ, USA; u Johnson & Johnson, Shanghai, China; v University of Lille, CHU Lille, Lille, France

Safety and efficacy of a dexamethasone-sparing regimenwith daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial

Manier S, et al.
Lancet Oncology
October 2025
Authors and Affiliates
Salomon Manier, Jérôme Lambert, Cyrille Hulin, Margaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Borhane Slama, Lionel Karlin, Frédéric Orsini Piocelle, Mamoun Dib, Laurence Sanhes, Pierre Morel, Abderazzak El Yamani, Mourad Tiab, Reza Tabrizi, Valentine Richez, Laurent Garderet, Bruno Royer, Benoit Bareau, Clara Mariette, Emmanuel Fleck, Daniela Robu, Claire Calmettes, Sophie Rigaudeau, Hélène Demarquette, Laurent Frenzel, Olivier Decaux, Mohamad Mohty, Bertrand Arnulf, Noémie Bigot, Aurore Perrot, Jill Corre, Jean-Yves Mary, Hervé Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon Department of Hematology, University Hospital of Lille, Lille, France (Prof S Manier MD PhD, Prof T Facon MD), Department of Biostatistics and Epidemiology (Prof J Lambert MD PhD, N Bigot MSc, J-Y Mary PhD), and Department of Hematology (B Royer MD, Prof B Arnulf MD PhD), University Hospital of SaintLouis, Paris, France; Department of Hematology, University Hospital of Bordeaux, Bordeaux, France (C Hulin MD); Department of Hematology, University Hospital of Caen Normandie, Caen, France (M Macro MD); Department of Hematology, Le Mans Hospital, Le Mans, France (K Laribi MD); Department of Hematology, Côte Basque Hospital, Bayonne, France (C Araujo MD); Department of Hematology, Metropole Savoie Hospital, Chambéry, France (G M Pica MD); Department of Hematology, University Hospital of Nantes, Nantes, France (Prof C Touzeau MD PhD, Prof P Moreau MD PhD); Department of Hematology, Bretagne-Atlantique Hospital, Vannes, France (P Godmer MD); Department of Hematology, Avignon Hospital, France (B Slama MD); Department of Hematology, University Hospital of Lyon, Hospices Civils de Lyon, Lyon, France (L Karlin MD); Department of Hematology, Annecy Genevois Hospital, Annecy, France (F Orsini Piocelle MD); Department of Hematology, University Hospital of Angers, Angers, France (M Dib MD); Department of Hematology, Perpignan Hospital, Perpignan, France (L Sanhes MD); Department of Hematology, University Hospital of Amiens, Amiens, France (Prof P Morel MD PhD); Department of Hematology, Simone Veil Hospital, Blois, France (A El Yamani MD); Department of Hematology, La Roche-sur-Yon Hospital, La Roche-sur-Yon, France (M Tiab MD); Department of Hematology, Mont-De-Marsan Hospital, Mont-De-Marsan, France (R Tabrizi MD); Department of Hematology, University Hospital of Nice, Nice, France (V Richez MD); Department of Hematology, University Hospital of Pitié Salpetriere, Paris, France (L Garderet MD PhD); Department of Hematology, Les Hôpitaux Privés Rennais, Cesson Sévigné, France (B Bareau MD); Department of Hematology, University Hospital of Grenoble, Grenoble, France (C Mariette MD); Department of Hematology, La Rochelle Ré Aunis Hospital, La Rochelle, France (E Fleck MD); Department of Hematology, Lens Hospital, Lens, France (D Robu MD); Department ofHematology, Périgueux Hospital, Périgueux, France (C Calmettes MD); Department of Hématologie, Versaille Hospital, Le ChesnayRocquencourt, France (S Rigaudeau MD); Department of Hématologie, Dunkerque Hospital, Dunkerque, France (H Demarquette MD); Department of Hematology, University Hospital of Necker, Paris, France (L Frenzel MD PhD); Department of Hematology, University Hospital of Rennes, Rennes, France (Prof O Decaux MD PhD); Department of Hematology, Sorbonne University, SaintAntoine Hospital, Paris, France (Prof M Mohty MD PhD); Department of Hematology (Prof A Perrot MD PhD) and Unit for Genomics in Myeloma (Prof J Corre PharmaD PhD, Prof H Avet-Loiseau MD PhD), University Hospital of Toulouse–Oncopole, Toulouse, France; Department of Hematology, University Hospital of Poitiers, Poitiers, France (Prof X Leleu MD PhD)

Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure‑Response Analysis of the DREAMM‑8 Study

Hanafin P, et al.
Targeted Oncology
September 2025
Authors and Affiliates
Patrick Hanafn1  · Yu Liu Ho1  · Theodoros Papathanasiou2  · Giulia Fulci3  · Neal Sule1  · Brandon E Kremer1  · Geraldine Ferron‑Brady1 1 GSK, 1250 S Collegeville Rd, Collegeville, PA 19426, USA 2 GSK, Baar, Switzerland 3 GSK, Waltham, MA, USA

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma

Gautam S, et al.
J Manag Care Spec Pharm
September 2025
Authors and Affiliates
Santosh Gautam, PhD; Laura Morrison, MPH; Philippe Thompson-Leduc, MSc; Bronwyn Moore, BA; Gordon Wong, BA; Brian Macomson, PharmD; Vipin Khare, MD; Niodita Gupta-Werner, MD, MPH, PhD; Rohan Medhekar, PhD Johnson & Johnson, Horsham, PA (Gautam, Macomson, Khare, Gupta-Werner, Medhekar); Analysis Group ULC, Montréal, QC, Canada (Morrison, Thompson-Leduc, Moore, Wong)

HLA-A*03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis

Zhang BC, et al.
EBio Medicine
September 2025
Authors and Affiliates
Brian C. Zhang, Tilman Schneider-Hohendorf, Rebecca Elyanow, Beatrice Pignolet, Simon Falk, Christian Wünsch, Marie Deffner, Erik Yusko, Damon May, Daniel Mattox, Eva Dawin, Lisa Ann Gerdes, Florence Bucciarelli, Lisa Revie, Gisela Antony, Sven Jarius, Christiane Seidel, Makbule Senel, Stefan Bittner, Felix Luessi, Joachim Havla, Matthias Knop, Manuel A. Friese, Susanne Rothacher, Anke Salmen, Fumie Hayashi, Roland Henry, Stacy Caillier, Adam Santaniello, University of California San Francisco MS-EPIC Team, German Competence Network Multiple Sclerosis (KKNMS), Maria Seipelt, Christoph Heesen, Sandra Nischwitz, Antonios Bayas, Hayrettin Tumani, Florian Then Bergh, Gerd Meyer zu Hörste, Tania Kümpfel, Catharina C. Gross, Brigitte Wildemann, Martin Kerschensteiner, Ralf Gold, Sven G. Meuth, Frauke Zipp, Bruce A. C. Cree, Jorge Oksenberg, Michael R. Wilson, Stephen L. Hauser, Scott S. Zamvil, Luisa Klotz, Roland Liblau.

Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study

Yoroidaka T, et al.
Haematologica
September 2025
Authors and Affiliates
Takeshi Yoroidaka,1* Hiroyuki Takamatsu,1* Ryota Urushihara,2 Mitsuhiro Itagaki,3 Satoshi Yoshihara,4 Kota Sato,5 Naoki Takezako,6 Shuji Ozaki,7 Kazuhito Suzuki,8 Kentaro Kohno,9 Tsuyoshi Muta,3 Morio Matsumoto,10 Yasushi Terasaki,11 Takeshi Yamashita,12 Shin-ichi Fuchida,13 Jun Sakamoto,14 Tadao Ishida,5 Kenshi Suzuki,5 Hirokazu Murakami,15 Brian G. M. Durie16 and Kazuyuki Shimizu17 1 Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan; 2Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan; 3Department of Hematology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan; 4Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Nishinomiya, Japan; 5Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan; 6Department of Hematology, Nerima Hikarigaoka Hospital, Tokyo, Japan; 7 Department of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan; 8Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; 9Department of Hematology, Japan Community Healthcare Organization Kyusyu Hospital, Kitakyushu, Japan; 10Department of Hematology, NHO Shibukawa Medical Center, Shibukawa, Japan; 11Division of Hematology, Toyama City Hospital, Toyama, Japan; 12Department of Hematology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan; 13Department of Hematology, Japan Community Health care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan; 14Bio Medical Laboratories (BML), INC., Kawagoe, Japan; 15Faculty of Medical Technology and Clinical Engineering, Gunma University of Health and Welfare, Maebashi, Japan; 16Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA and 17Department of Hematology, Higashi Nagoya National Hospital, Nagoya, Japan
Previous Next